Biosense Webster enters new contract with Stereotaxis to deploy Odyssey products Stereotaxis.

announced today that it offers entered into a fresh strategic collaboration with Biosense Webster, Inc. This contract marks the broadest & most committed cooperative contract around Odyssey to day. ‘The curiosity in Odyssey is growing at an impressive price,’ stated Michael P. Kaminski, Stereotaxis CEO and President.’ By leveraging Odyssey’s exclusive clinical features, Stereotaxis and Biosense Webster plan to transform EP labs right into a streamlined workflow environment that’s optimized to provide patient care even beneath the most demanding circumstances.Panic and other psychological symptoms showed significant reductions in the CBT group also. High levels of pretreatment anxiousness predicted reduces in the 3 hypochondriasis scores after managing for the effects of depression, age, sex, educational level, work status, and marital position. High anxiety at entry into the CBT plan predicted an improved treatment outcome.

Canon receives FDA 510 clearance for CX-1 Hybrid Mydriatic/Non-Mydriatic Digital Retinal Camera Canon U.S.A., Inc., a head in medical imaging, today announced the Canon CX-1 Hybrid Mydriatic/Non-Mydriatic Digital Retinal Camcorder offers received 510 clearance from the U.S.